Immunogen (NASDAQ: IMGN) reported Q4 EPS of ($0.51), $0.12 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $7.41 million versus the consensus estimate of $17.11 million.

For earnings history and earnings-related data on Immunogen (IMGN) click here.